(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
12 June 2014 (12.06.2014)

WIPO | PCT

(10) International Publication Number
WO 2014/088785 A1

(51) International Patent Classification:
A61K 31/7088 (2006.01) *A61P 35/02* (2006.01)
A61K 31/7125 (2006.01) *A61P 7/00* (2006.01)
A61P 35/00 (2006.01) *A61P 7/06* (2006.01)

(21) International Application Number:
PCT/US2013/070437

(22) International Filing Date:
15 November 2013 (15.11.2013)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/734,941 7 December 2012 (07.12.2012) US
61/799,069 15 March 2013 (15.03.2013) US
13/841,711 15 March 2013 (15.03.2013) US
61/900,347 5 November 2013 (05.11.2013) US

(71) Applicant: **GERON CORPORATION** [US/US]; 149 Commonwealth Drive, Menlo Park, CA 94025 (US).

(72) Inventors: **STUART, Monic, J.**; 2828 Churchill Drive, Hillsbouough, CA 94010 (US). **KELSEY, Stephen**; 1468 Hamilton Avenue, Palo Alto, CA 94301 (US).

(74) Agents: **SHOW, Matthew, D.** et al.; Morrison & Foerster LLP, 755 Page Mill Road, Palo Alto, CA 94304-1018 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

[Continued on next page]

(54) Title: USE OF TELOMERASE INHIBITORS FOR THE TREATMENT OF MYELOPROLIFERATIVE DISORDERS AND MYELOPROLIFERATIVE NEOPLASMS

Figure 1

A



	Day 0	Day 1	Day 2	Day 3	Day 4	Day 5	Day 6	Day 7	Day 10	Day 14	Day 17
Imetelstat 0.9 uM	2.00	2.00	3.11	3.89	9.89	18.78	29.75	44.33	138.0	37.67	35.30
Imetelstat 1.875 uM	2.00	2.67	3.22	6.00	7.44	21.56	30.75	55.50	115.0	45.67	39.70
Imetelstat 3.75 uM	2.00	1.56	2.56	5.00	8.11	16.44	27.00	38.33	101.0	39.67	56.00
Imetelstat 7.5 uM	2.00	1.44	2.00	4.56	10.44	15.44	26.75	41.00	96.50	46.33	52.30
Imetelstat 15 uM	2.00	1.89	3.00	4.78	7.56	15.56	25.20	39.33	107.5	36.33	35.70
Standard Control	2.00	2.00	2.44	4.33	9.22	15.33	25.33	56.00	141.0	18.83	38.70
Solvent Control	2.00	2.56	3.33	4.67	11.22	15.33	31.25	42.33	127.0	20.00	37.70

(57) Abstract: Provided herein are methods for reducing neoplastic progenitor cell proliferation and alleviating symptoms associated in individuals diagnosed with or thought to have myeloproliferative disorders, such as Essential Thrombocythemia (ET). Also provided herein are methods for using telomerase inhibitors for maintaining blood platelet counts at relatively normal ranges in the blood of individuals diagnosed with or suspected of having myeloproliferative disorders, such as ET.

WO 2014/088785 A1

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*